Centrioles: One master to rule them all
Multiciliated cells rely on the same master regulator as dividing cells to amplify the number of centrioles needed to generate the hair-like structures that coat their cell surface.
- Departamento de Bioquímica, Facultad de Medicina, Universidad Autónoma de Madrid, Spain
- Instituto de Investigaciones Biomédicas “Alberto Sols”, Consejo Superior de Investigaciones Científicas, Spain
- CIBER de Enfermedades Raras, Instituto de Salud Carlos III, Spain
The skeleton of filaments that gives animal and other eukaryotic cells their shape is organized in large part by two cylindrical structures called centrioles. Every cell cycle, the centrioles duplicate to form the mitotic spindle that separates the cell’s genetic material evenly between the daughter cells during cell division (Figure 1A). If the centrioles fail to replicate or too many are made, this can lead to diseases like cancer or microcephaly (Nigg and Holland, 2018).
Figure 1
PLK4 is essential for centriole assembly in both cycling cells and differentiating multiciliated cells.
(A) In the first phase of the cell cycle (known as G1), each cell contains two centrioles (grey cylinders): the mother centriole, which is fully mature and contains appendages, and the daughter centriole, which is younger and appendage-free. These centrioles are tethered together and surrounded by an amorphous mass of protein known as the pericentriolar matrix. As cells replicate their DNA (S-phase), each centriole duplicates to form new ‘procentrioles’ via a mechanism regulated by the enzyme PLK4. The procentrioles then elongate into fully formed centrioles. By the G2 phase of the cycle, cells have two pairs of centrioles, which form the mitotic spindle during mitosis (M-phase). The spindle then segregates the centrioles and the cell’s genetic material evenly among the daughter cells. (B) Multiciliated cells (MCCs) arise from progenitor cells that exit their last mitosis with two centrioles, as shown above. During differentiation, these parental centrioles are amplified via two distinct mechanisms: parental centrioles duplicating multiple times to produce new centrioles (top), or centrioles being built from scratch (bottom) using spheroidal, transitory organelles called deuterosomes. Eventually, all the centrioles mature and migrate to the apical surface where they dock to the membrane and form the cell’s cilia. In progenitor cells lacking the enzyme PLK4, neither of these pathways are functional and the cells are unable to differentiate into multiciliated cells.
Image credit: Pablo Barbeito and Francesc R. Garcia-Gonzalo.
Centrioles are also responsible for forming hair-like structures known as cilia, which protrude from the body of certain cells. Some epithelial cells have hundreds of cilia attached to their apical surface, which function like oars in a galley, collectively beating to displace extracellular fluid. These multiciliated cells can be found lining the surface of several organs, including the trachea, reproductive tissues, and the ventricular system in the brain. However, defects in these cells can lead to respiratory infections, infertility, and other cilia-associated disorders (Reiter and Leroux, 2017).
Multiciliated cells arise during development from epithelial progenitor cells that each contain a single centriole pair. To form the hundreds of cilia that will coat the apical surface, the progenitors increase their centriole content either by copying the original pair multiple times, or by building new centrioles in transitory structures called deuterosomes (Figure 1B; Nanjundappa et al., 2019).
During this amplification process (known as A-phase), the levels of an enzyme called PLK4 (short for Polo-like kinase 4) increase, and the enzyme associates with the parental centrioles and deuterosomes (Hoh et al., 2012; Zhao et al., 2013). This protein is the master regulator of centriole assembly and duplication during cell division. However, recent studies found that blocking PLK4 – either with a drug or by silencing its expression – did not prevent multiciliated cells from developing the right number of centrioles and cilia, despite causing a delay in A-phase (Nanjundappa et al., 2019; Mercey et al., 2019a; Mercey et al., 2019b; Zhao et al., 2019; Wong et al., 2015). This led to the conclusion that PLK4 is dispensable for centriole amplification in epithelial progenitors. Now, in eLife, Andrew Holland and co-workers from Johns Hopkins University – including Gina LoMastro as first author – report new results that contradict this theory (LoMastro et al., 2022).
The team created mouse models which contained a modified version of the gene that encodes PLK4: in cells expressing another enzyme called Cre recombinase, the PLK4 gene no longer produced the protein, or only produced an enzymatically inactive form. LoMastro et al. found that epithelial progenitor cells lacking PLK4, or those with a non-functioning version, were unable to amplify their centrioles. Furthermore, the mutant cells could not differentiate into the multiciliated cells in the trachea or the ependymal cells lining the ventricular system in the brain, both in vitro and in vivo.
These findings provide strong evidence that PLK4 and its enzymatic activity are essential for centriole amplification in multiciliated cells. So, why did several high-quality studies appear to show the opposite result? LoMastro et al. found that when the concentration of the drug used in the previous studies was increased (from 1.5 µM to 5–10 µM), it was able to inhibit centriole amplification in ependymal and tracheal multiciliated cells. This suggests that the dose of drug needed to block A-phase is much higher than the amount required to inhibit centriole duplication in cycling cells – which makes sense given that the level of PLK4 is many times higher in A-phase than during the cell cycle (Hoh et al., 2012). Furthermore, LoMastro et al. found that multiciliated cells in the trachea have specialized proteins that pump out the inhibitor, which likely reduced the effectiveness of the drug.
Low drug doses are only part of the story. Previous studies also failed to block A-phase by silencing the expression of the gene for PLK4 using a method called RNAi, even when this was supplemented with the inhibiting drug (Nanjundappa et al., 2019; Zhao et al., 2019). It has since been discovered that the kinetics of building centrioles from scratch are highly dependent on the amount of PLK4 (Nabais et al., 2021), suggesting that cells can tell the difference between having little amounts of the enzyme and none at all. Unlike the Cre recombinase approach used by LoMastro et al., the RNAi technique does not fully eliminate gene expression and cells are likely to still have very low levels of the protein. This small amount of PLK4 may be enough to drive A-phase, which may explain why the epithelial progenitor cells in these prior experiments were still able to amplify their number of centrioles.
The drug may have failed to potentiate the effects of RNAi due to insufficient levels of the inhibitor being administered. Furthermore, this drug is known to increase PLK4 levels by preventing the protein from phosphorylating itself so it can be degraded (Nigg and Holland, 2018). Therefore, if the drug is only partially effective and inhibits some but not all PLK4 molecules, protein levels might still be able to rise, exacerbating the number of PLK4 enzymes that remain unblocked.
Further experiments are needed to investigate these possibilities. Nevertheless, it seems clear that PLK4 is the master of centriole assembly, with multiciliated cells being no exception. Several important questions remain. For instance, much remains unknown about the molecular mechanisms PLK4 activates to drive centriole assembly in cycling and multiciliated cells. In addition, it is poorly understood how the quantity of centrioles is coordinated with the size of the cell’s apical surface. LoMastro et al. found that the apical surface was smaller in PLK4 mutants that were unable to undergo centriole amplification. Since previous studies also found that expanding the apical surface leads to higher centriole numbers, this suggests that both processes are tightly coordinated (Nanjundappa et al., 2019; Kulkarni et al., 2021). Understanding how PLK4 regulates the relationship between cell shape and centriole number will be one of the next frontiers in the field.
References
-
Plk4 triggers autonomous de novo centriole biogenesis and maturationThe Journal of Cell Biology 220:e202008090.https://doi.org/10.1083/jcb.202008090
-
Genes and molecular pathways underpinning ciliopathiesNature Reviews 18:533–547.https://doi.org/10.1038/nrm.2017.60
Article and author information
Author details
Francesc R Garcia-Gonzalo
Publication history
Copyright
© 2022, Barbeito and Garcia-Gonzalo
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,175
- views
-
- 133
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Centrioles: One master to rule them all
eLife 11:e82873.
https://doi.org/10.7554/eLife.82873
Further reading
-
- Cell Biology
Dynamic interactions between gut mucosal cells and the external environment are essential to maintain gut homeostasis. Enterochromaffin (EC) cells transduce both chemical and mechanical signals and produce 5-hydroxytryptamine to mediate disparate physiological responses. However, the molecular and cellular basis for functional diversity of ECs remains to be adequately defined. Here, we integrated single-cell transcriptomics with spatial image analysis to identify 14 EC clusters that are topographically organized along the gut. Subtypes predicted to be sensitive to the chemical environment and mechanical forces were identified that express distinct transcription factors and hormones. A Piezo2+ population in the distal colon was endowed with a distinctive neuronal signature. Using a combination of genetic, chemogenetic, and pharmacological approaches, we demonstrated Piezo2+ ECs are required for normal colon motility. Our study constructs a molecular map for ECs and offers a framework for deconvoluting EC cells with pleiotropic functions.
-
- Cell Biology
Niemann–Pick disease type C (NPC) is a devastating lysosomal storage disease characterized by abnormal cholesterol accumulation in lysosomes. Currently, there is no treatment for NPC. Transcription factor EB (TFEB), a member of the microphthalmia transcription factors (MiTF), has emerged as a master regulator of lysosomal function and promoted the clearance of substrates stored in cells. However, it is not known whether TFEB plays a role in cholesterol clearance in NPC disease. Here, we show that transgenic overexpression of TFEB, but not TFE3 (another member of MiTF family) facilitates cholesterol clearance in various NPC1 cell models. Pharmacological activation of TFEB by sulforaphane (SFN), a previously identified natural small-molecule TFEB agonist by us, can dramatically ameliorate cholesterol accumulation in human and mouse NPC1 cell models. In NPC1 cells, SFN induces TFEB nuclear translocation via a ROS-Ca2+-calcineurin-dependent but MTOR-independent pathway and upregulates the expression of TFEB-downstream genes, promoting lysosomal exocytosis and biogenesis. While genetic inhibition of TFEB abolishes the cholesterol clearance and exocytosis effect by SFN. In the NPC1 mouse model, SFN dephosphorylates/activates TFEB in the brain and exhibits potent efficacy of rescuing the loss of Purkinje cells and body weight. Hence, pharmacological upregulating lysosome machinery via targeting TFEB represents a promising approach to treat NPC and related lysosomal storage diseases, and provides the possibility of TFEB agonists, that is, SFN as potential NPC therapeutic candidates.
